71 related articles for article (PubMed ID: 38388484)
21. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
22. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
[TBL] [Abstract][Full Text] [Related]
23. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.
Lee TK; Guan XY; Ma S
Nat Rev Gastroenterol Hepatol; 2022 Jan; 19(1):26-44. PubMed ID: 34504325
[TBL] [Abstract][Full Text] [Related]
24. Interleukins in cancer: from biology to therapy.
Briukhovetska D; Dörr J; Endres S; Libby P; Dinarello CA; Kobold S
Nat Rev Cancer; 2021 Aug; 21(8):481-499. PubMed ID: 34083781
[TBL] [Abstract][Full Text] [Related]
25. MDSC: Markers, development, states, and unaddressed complexity.
Hegde S; Leader AM; Merad M
Immunity; 2021 May; 54(5):875-884. PubMed ID: 33979585
[TBL] [Abstract][Full Text] [Related]
26. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
27. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.
Ruf B; Heinrich B; Greten TF
Cell Mol Immunol; 2021 Jan; 18(1):112-127. PubMed ID: 33235387
[TBL] [Abstract][Full Text] [Related]
28. Function and regulation of the PEA3 subfamily of ETS transcription factors in cancer.
Qi T; Qu Q; Li G; Wang J; Zhu H; Yang Z; Sun Y; Lu Q; Qu J
Am J Cancer Res; 2020; 10(10):3083-3105. PubMed ID: 33163259
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of LAPTM4B Contributes to the Impairment of the Autophagic Flux via Unopposed Activation of mTORC1 Signaling During Myocardial Ischemia/Reperfusion Injury.
Gu S; Tan J; Li Q; Liu S; Ma J; Zheng Y; Liu J; Bi W; Sha P; Li X; Wei M; Cao N; Yang HT
Circ Res; 2020 Sep; 127(7):e148-e165. PubMed ID: 32693673
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
31. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
[TBL] [Abstract][Full Text] [Related]
32. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
Li BH; Garstka MA; Li ZF
Mol Immunol; 2020 Jan; 117():201-215. PubMed ID: 31835202
[TBL] [Abstract][Full Text] [Related]
33. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.
Greten TF; Lai CW; Li G; Staveley-O'Carroll KF
Gastroenterology; 2019 Jan; 156(2):510-524. PubMed ID: 30287171
[TBL] [Abstract][Full Text] [Related]
34. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
Ren Z; Li A; Jiang J; Zhou L; Yu Z; Lu H; Xie H; Chen X; Shao L; Zhang R; Xu S; Zhang H; Cui G; Chen X; Sun R; Wen H; Lerut JP; Kan Q; Li L; Zheng S
Gut; 2019 Jun; 68(6):1014-1023. PubMed ID: 30045880
[TBL] [Abstract][Full Text] [Related]
35. Cancer immunotherapy using checkpoint blockade.
Ribas A; Wolchok JD
Science; 2018 Mar; 359(6382):1350-1355. PubMed ID: 29567705
[TBL] [Abstract][Full Text] [Related]
36. AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis, while reducing chemotherapy sensitivity.
Meng Y; Wang L; Xu J; Zhang Q
Mol Oncol; 2018 Mar; 12(3):373-390. PubMed ID: 29337428
[TBL] [Abstract][Full Text] [Related]
37. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
38. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.
Ha H; Debnath B; Neamati N
Theranostics; 2017; 7(6):1543-1588. PubMed ID: 28529637
[TBL] [Abstract][Full Text] [Related]
39. The CXCL8-CXCR1/2 pathways in cancer.
Liu Q; Li A; Tian Y; Wu JD; Liu Y; Li T; Chen Y; Han X; Wu K
Cytokine Growth Factor Rev; 2016 Oct; 31():61-71. PubMed ID: 27578214
[TBL] [Abstract][Full Text] [Related]
40. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
